- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Enasidenib is an oral, reversible, selective inhibitor of mutated isocitrate dehydrogenase (IDH) 2.1,2?In vitro studies suggest that the oncometabolite 2-hydroxyglutarate (2-HG), which is present at high levels in patients with IDH mutations,3-5?may drive epigenetic changes that block normal cellular differentiation, leading to a cancerous state.2,4?As demonstrated in preclinical studies, enasidenib binds and inhibits the mutant IDH2 enzyme that is responsible for the accumulation of 2-HG.2
Enasidenib Hypothesized Mechanism of Action
Enasidenib is a selective inhibitor of mutant IDH2 and has been hypothesized to reduce 2-HG levels which may restore DNA demethylation in acute myeloid leukemia.